Screening and confirmation criteria for hormone residue analysis using liquid chromatography accurate mass time-of-flight, Fourier transform ion cyclotron resonance and orbitrap mass spectrometry techniques

An emerging trend is recognised in hormone and veterinary drug residue analysis from liquid chromatography tandem mass spectrometry (LC/MS/MS) based screening and confirmation towards accurate mass alternatives such as LC coupled with time-of-flight (TOF), Fourier transform ion cyclotron resonance (...

Full description

Saved in:
Bibliographic Details
Published in:Analytica chimica acta 2007-03, Vol.586 (1-2), p.122-129
Main Authors: Nielen, M.W.F., van Engelen, M.C., Zuiderent, R., Ramaker, R.
Format: Article
Language:English
Subjects:
Accurate mass
Analytical chemistry
Animals
Chemistry
Chemistry Techniques, Analytical - methods
Chromatographic methods and physical methods associated with chromatography
Chromatography, Liquid - methods
Clenbuterol - chemistry
Criteria
Cyclotrons
Drug Residues - analysis
Exact sciences and technology
Fourier Analysis
Fourier transform mass spectrometry
Ions
Liquid chromatography mass spectrometry
Mass Spectrometry - methods
Models, Chemical
Orbitrap
Other chromatographic methods
Reproducibility of Results
Residue analysis
Sensitivity and Specificity
Spectrometric and optical methods
Spectrometry, Mass, Electrospray Ionization - methods
Stanozolol - analysis
Steroid
Steroids - analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An emerging trend is recognised in hormone and veterinary drug residue analysis from liquid chromatography tandem mass spectrometry (LC/MS/MS) based screening and confirmation towards accurate mass alternatives such as LC coupled with time-of-flight (TOF), Fourier transform ion cyclotron resonance (FTICR) or Fourier transform orbitrap (FT Orbitrap) MS. In this study, mass resolution and accuracy are discussed for LC/MS screening and confirmation of targeted analytes and for the identification of unknowns using the anabolic steroid stanozolol and the designer β-agonist “Clenbuterol-R” as model substances. It is shown theoretically and experimentally that mass accuracy criteria without proper mass resolution criteria yield false compliant (false negative) results, both in MS screening and MS/MS confirmation of stanozolol. On the other hand, previous medium resolution accurate mass TOFMS/MS data of the designer β-agonist were fully confirmed by high resolution FT Orbitrap MSn experiments. A discussion is initiated through a proposal for additional criteria for the use of accurate mass LC/MS technologies, to be implemented in Commission Decision 2002/657/EC.
ISSN:0003-2670
1873-4324
DOI:10.1016/j.aca.2006.08.055